A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After NAC in TNBC

PHASE2RecruitingINTERVENTIONAL

Enrollment

460

Participants

Timeline

Start Date

August 3, 2020

Primary Completion Date

August 31, 2027

Study Completion Date

August 31, 2032

Conditions

Triple-negative Breast Cancer

Interventions

DRUG

Tislelizumab

200mg, q3w, for 1 year

DRUG

capecitabine

600-750 mg/m2 PO Bid，continuous, for 1 year

Trial Locations (1)

RECRUITING

Sunyat-sen Memorial Hospital, Guandong

All Listed Sponsors

lead

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

OTHER

NCT04501523 - A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After NAC in TNBC | Biotech Hunter | Biotech Hunter